GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » NeoGenomics Inc (NAS:NEO) » Definitions » Pretax Margin %

NeoGenomics (NeoGenomics) Pretax Margin % : -17.72% (As of Mar. 2024)


View and export this data going back to 1996. Start your Free Trial

What is NeoGenomics Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. NeoGenomics's Pre-Tax Income for the three months ended in Mar. 2024 was $-27.7 Mil. NeoGenomics's Revenue for the three months ended in Mar. 2024 was $156.2 Mil. Therefore, NeoGenomics's pretax margin for the quarter that ended in Mar. 2024 was -17.72%.

The historical rank and industry rank for NeoGenomics's Pretax Margin % or its related term are showing as below:

NEO' s Pretax Margin % Range Over the Past 10 Years
Min: -31.26   Med: -3.14   Max: 1.48
Current: -14.91


NEO's Pretax Margin % is ranked worse than
50.92% of 218 companies
in the Medical Diagnostics & Research industry
Industry Median: -13.725 vs NEO: -14.91

NeoGenomics Pretax Margin % Historical Data

The historical data trend for NeoGenomics's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NeoGenomics Pretax Margin % Chart

NeoGenomics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.89 -3.16 -3.11 -31.26 -16.41

NeoGenomics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -24.57 -18.13 -14.12 -9.83 -17.72

Competitive Comparison of NeoGenomics's Pretax Margin %

For the Diagnostics & Research subindustry, NeoGenomics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeoGenomics's Pretax Margin % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, NeoGenomics's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where NeoGenomics's Pretax Margin % falls into.



NeoGenomics Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

NeoGenomics's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-97.097/591.643
=-16.41 %

NeoGenomics's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as

Pretax Margin=Pre-Tax Income (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-27.681/156.24
=-17.72 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NeoGenomics  (NAS:NEO) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


NeoGenomics Pretax Margin % Related Terms

Thank you for viewing the detailed overview of NeoGenomics's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


NeoGenomics (NeoGenomics) Business Description

Traded in Other Exchanges
Address
9490 NeoGenomics Way, Fort Myers, FL, USA, 33912
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Pharma Services. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. The company generates revenue from Clinical Services.
Executives
Alicia C Olivo officer: General Counsel 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Anthony P. Zook director C/O VIVUS, INC., 351 EAST EVELYN AVENUE, MOUNTAIN VIEW CA 94041
Elizabeth Floegel director 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Neil Gunn director 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Greg D Aunan officer: Chief Accounting Officer HMS HOLDINGS CORP., 5615 HIGH POINT DRIVE, IRVING TX 75038
Jeffrey Scott Sherman officer: Chief Financial Officer 103 POWELL COURT, SUITE 200, BRENTWOOD TN 37027
Melody Harris officer: President, Enterprise Ops 4801 WEST BYRON PLACE, DENVER CO 80211
Warren Stone officer: President, Clinical Services 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
David Brian Perez director 12100 6TH AVENUE, LAKEWOOD CO 80228
Christopher M Smith officer: Chief Executive Officer 125 CONSTITUTION DRIVE, MENLO PARK CA 94025
Shashikant Kulkarni officer: President of Lab Operations 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
Vishal Sikri officer: President and CCO, Inivata 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
David Sholehvar officer: President, Clinical Services 9490 NEOGENOMICS WAY, FORT MYERS FL 33912
William Bonello officer: VP, Investor Relations 12780 WESTLINKS DRIVE, FORT MYERS FL 33913
Kathryn B Mckenzie officer: Principal Accounting Officer 12780 WESTLINKS DRIVE, FORT MYERS FL 33913

NeoGenomics (NeoGenomics) Headlines

From GuruFocus

NeoGenomics Inc's Stock Performance: A Detailed Analysis

By GuruFocus Research 11-14-2023